Your browser doesn't support javascript.
loading
Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders.
Lu, Angelo; Zimmermann, Hanna G; Specovius, Svenja; Motamedi, Seyedamirhosein; Chien, Claudia; Bereuter, Charlotte; Lana-Peixoto, Marco A; Fontenelle, Mariana Andrade; Ashtari, Fereshteh; Kafieh, Rahele; Dehghani, Alireza; Pourazizi, Mohsen; Pandit, Lekha; D'Cunha, Anitha; Kim, Ho Jin; Hyun, Jae-Won; Jung, Su-Kyung; Leocani, Letizia; Pisa, Marco; Radaelli, Marta; Siritho, Sasitorn; May, Eugene F; Tongco, Caryl; De Sèze, Jérôme; Senger, Thomas; Palace, Jacqueline; Roca-Fernández, Adriana; Leite, Maria Isabel; Sharma, Srilakshmi M; Stiebel-Kalish, Hadas; Asgari, Nasrin; Soelberg, Kerstin Kathrine; Martinez-Lapiscina, Elena H; Havla, Joachim; Mao-Draayer, Yang; Rimler, Zoe; Reid, Allyson; Marignier, Romain; Cobo-Calvo, Alvaro; Altintas, Ayse; Tanriverdi, Uygur; Yildirim, Rengin; Aktas, Orhan; Ringelstein, Marius; Albrecht, Philipp; Tavares, Ivan Maynart; Bichuetti, Denis Bernardi; Jacob, Anu; Huda, Saif; Soto de Castillo, Ibis.
Afiliación
  • Lu A; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Zimmermann HG; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Specovius S; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Motamedi S; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Chien C; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Bereuter C; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Lana-Peixoto MA; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Fontenelle MA; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Ashtari F; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kafieh R; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Dehghani A; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Pourazizi M; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Pandit L; CIEM MS Research Center, University of Minas Gerais State, Medical School, Belo Horizonte, Brazil.
  • D'Cunha A; CIEM MS Research Center, University of Minas Gerais State, Medical School, Belo Horizonte, Brazil.
  • Kim HJ; Kashani MS Center, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).
  • Hyun JW; School of Advanced Technologies in Medicine, Medical Image and Signal Processing Research Center, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).
  • Jung SK; Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).
  • Leocani L; Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).
  • Pisa M; Center for Advanced Neurological Research, Nitte University, Mangalore, Karnataka, India.
  • Radaelli M; Center for Advanced Neurological Research, Nitte University, Mangalore, Karnataka, India.
  • Siritho S; Department of Neurology, National Cancer Center Korea, Goyang-si, Korea (the Republic of).
  • May EF; Department of Neurology, National Cancer Center Korea, Goyang-si, Korea (the Republic of).
  • Tongco C; Department of Opthalmology, Research Institute and Hospital of National Cancer Center, Goyang, Korea (the Republic of).
  • De Sèze J; Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE) Scientific Institute, Hospital San Raffaele and University Vita-Salute San Raffaele, Milano, Italy.
  • Senger T; Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE) Scientific Institute, Hospital San Raffaele and University Vita-Salute San Raffaele, Milano, Italy.
  • Palace J; Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE) Scientific Institute, Hospital San Raffaele and University Vita-Salute San Raffaele, Milano, Italy.
  • Roca-Fernández A; Division of Neurology, Department of Medicine, Siriraj Hospital and Bumrungrad International Hospital, Bangkok, Thailand.
  • Leite MI; Swedish Neuroscience Institute Neuro-Ophthalmology, Seattle, Washington, USA.
  • Sharma SM; Swedish Neuroscience Institute Neuro-Ophthalmology, Seattle, Washington, USA.
  • Stiebel-Kalish H; Department of Neurology, Neurology Service, University Hospital of Strasbourg, Strasbourg, France.
  • Asgari N; Department of Neurology, Neurology Service, University Hospital of Strasbourg, Strasbourg, France.
  • Soelberg KK; Department of Neurology, Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, UK.
  • Martinez-Lapiscina EH; Department of Neurology, Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, UK.
  • Havla J; Department of Neurology, Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, UK.
  • Mao-Draayer Y; Department of Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, UK.
  • Rimler Z; Neuro-Opthalmology Division, Department of Opthalmology, Rabin Medical Center, Petah Tikva, Israel.
  • Reid A; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Marignier R; Department of Neurology Slagelse, Institutes of Regional Health Research andMolecular Medicine, University of Southern Denmark, Odense, Syddanmark, Denmark.
  • Cobo-Calvo A; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Altintas A; Hospital Clinic of Barcelona-Institut d'Investigacions, Biomèdiques August Pi Sunyer, University of Barcelona, Barcelona, Spain.
  • Tanriverdi U; Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universitat Munchen, Munich, Germany.
  • Yildirim R; Department of Neurology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Aktas O; NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, NYU, New York, New York, USA.
  • Ringelstein M; NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, NYU, New York, New York, USA.
  • Albrecht P; Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Hospital for Neurology Pierre Wertheimer, Lyon, France.
  • Tavares IM; Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Hospital for Neurology Pierre Wertheimer, Lyon, France.
  • Bichuetti DB; Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Jacob A; Department of Neurology, Koc University Research Center for Translational Medicine (KUTTAM), Koc University School of Medicine, Istanbul, Turkey.
  • Huda S; Cerrahpasa Faculty of Medicine, Department of Neurology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Soto de Castillo I; Department of Ophthalmology, Cerrahpasa Medical Faculty, Istanbul Universitesi, Fatih, Turkey.
J Neurol Neurosurg Psychiatry ; 93(2): 188-195, 2022 02.
Article en En | MEDLINE | ID: mdl-34711650
ABSTRACT

BACKGROUND:

Patients with anti-aquaporin-4 antibody seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorders (NMOSDs) frequently suffer from optic neuritis (ON) leading to severe retinal neuroaxonal damage. Further, the relationship of this retinal damage to a primary astrocytopathy in NMOSD is uncertain. Primary astrocytopathy has been suggested to cause ON-independent retinal damage and contribute to changes particularly in the outer plexiform layer (OPL) and outer nuclear layer (ONL), as reported in some earlier studies. However, these were limited in their sample size and contradictory as to the localisation. This study assesses outer retinal layer changes using optical coherence tomography (OCT) in a multicentre cross-sectional cohort.

METHOD:

197 patients who were AQP4-IgG+ and 32 myelin-oligodendrocyte-glycoprotein antibody seropositive (MOG-IgG+) patients were enrolled in this study along with 75 healthy controls. Participants underwent neurological examination and OCT with central postprocessing conducted at a single site.

RESULTS:

No significant thinning of OPL (25.02±2.03 µm) or ONL (61.63±7.04 µm) were observed in patients who were AQP4-IgG+ compared with patients who were MOG-IgG+ with comparable neuroaxonal damage (OPL 25.10±2.00 µm; ONL 64.71±7.87 µm) or healthy controls (OPL 24.58±1.64 µm; ONL 63.59±5.78 µm). Eyes of patients who were AQP4-IgG+ (19.84±5.09 µm, p=0.027) and MOG-IgG+ (19.82±4.78 µm, p=0.004) with a history of ON showed parafoveal OPL thinning compared with healthy controls (20.99±5.14 µm); this was not observed elsewhere.

CONCLUSION:

The results suggest that outer retinal layer loss is not a consistent component of retinal astrocytic damage in AQP4-IgG+ NMOSD. Longitudinal studies are necessary to determine if OPL and ONL are damaged in late disease due to retrograde trans-synaptic axonal degeneration and whether outer retinal dysfunction occurs despite any measurable structural correlates.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Retina / Neuromielitis Óptica / Acuaporina 4 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Retina / Neuromielitis Óptica / Acuaporina 4 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article